ArticleBMC infectious diseases2025
Dynamic changes of chronic hepatitis B patient with loss of surface antigen: a case report.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatitis B virus (HBV) infection remains a significant global health challenge, particularly in regions like China, where the prevalence of HBV carriers is high. We report the dynamic serological and virological changes in a chronic HBV patient who exhibited HBsAg loss and subsequent reversion, explore the complex molecular mechanisms of atypical serological profile. CASE PRESENTATION: A 65-year-old male with a 40-year history of chronic HBV infection presented with hepatocellular carcinoma (HCC). Over three years, the patient underwent multiple interventions, including transarterial chemoembolization (TACE) and targeted therapies. Serial monitoring revealed a gradual decline in HBsAg levels, leading to seronegativity, followed by HBsAg reversion two years later. HBV DNA levels were quantified at 1.45 × 10³ IU/mL during HBsAg seronegativity. Genetic analysis identified multiple mutations in the HBV S gene, potentially altering HBsAg structure and antigenicity, contributing to the atypical serological profile.
conclusionsThis case underscores the complexity of HBV serological dynamics in the context of chronic infection and cancer treatment. The observed HBsAg fluctuations highlight the need for vigilant monitoring and advanced diagnostic techniques, such as HBV DNA testing, in patients with chronic HBV, particularly those undergoing immunosuppressive therapies. The identified S gene mutations may explain the serological changes, emphasizing the importance of genetic analysis in understanding HBV evolution and guiding clinical treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.